Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

A randomized, placebo-controlled phase 3 trial of the PI3Kδ inhibitor leniolisib for activated PI3Kδ syndrome

Blood (2023) 141 (9): 971–983.

https://doi.org/10.1182/blood.2022018546

Published: 2023

Includes: Supplemental data

Journal Articles

Interim Analysis of Safety and Hematological Parameters of an Ongoing Long-Term Open-Label Extension Study of Investigational PI3Kδ Inhibitor Leniolisib for Patients with Activated PI3K Delta Syndrome (APDS) through December 2021

V. Koneti Rao, Sharon Webster, Anna Sediva, Alessandro Plebani, Catharina Schuetz, Anna Shcherbina, Virgil A.S.H. Dalm, Antonino Trizzino, Yulia Zharankova, Elaine Kulm, Alanvin Orpia, Lavenda Chirombo Kluczynski, Julia Körholz, Vassilios Lougaris, Yulia Rodina, Klaus Kucher, Kath Radford, Jason Bradt, Gulbu Uzel

Blood (2022) 140 (Supplement 1): 1643–1645.

https://doi.org/10.1182/blood-2022-160334

Published: 2022

Journal Articles

Safety and Efficacy of Long Term Suppression of PI3Kinase Pathway By Small Molecule PI3K-Delta Inhibitor, Leniolisib in Apds (Activated PI3Kδ Syndrome)

V. Koneti Rao, MD FRCPA, Sharon Webster, BSN, Virgil A.S.H. Dalm, MD, Anna Sediva, MD, P. Martin van Hagen, H. Michael Do, MD, Les Folio, MD, Maciej Cabanski, Marie-Anne Valentin, Stefan de Buck, Christoph Kalis, Anke Hasselberg, Christoph Burkhart, Klaus Kucher, MD, Birgitte Sloth, Gulbu Uzel, MD

Blood (2018) 132 (Supplement 1): 3706.

https://doi.org/10.1182/blood-2018-99-113426

Published: 2018

Journal Articles

Effective “activated PI3Kδ syndrome”–targeted therapy with the PI3Kδ inhibitor leniolisib

Blood (2017) 130 (21): 2307–2316.

https://doi.org/10.1182/blood-2017-08-801191

Published: 2017

Includes: Supplemental data

Journal Articles

Minitransplant Using Repeated Unrelated Donor Lymphocyte Infusions as a Treatment of Immunodeficiency in Complete DiGeorge Syndrome.

Renata Formankova, MD, Katerina Zdrahalova, MD, Petr Sedlacek, MD, PhD, Petra Keslova, MD, Ondrej Hrusak, MD, PhD, Ester Mejstrikova, MD, Tomas Kalina, MD, Hana Zizkova, MD, Anna Sediva, MD, PhD, Jirina Bartunkova, MD, PhD, Karel Dlask, MD, Jan Stary, MD, PhD

Blood (2005) 106 (11): 5438.

https://doi.org/10.1182/blood.V106.11.5438.5438

Published: 2005

NARROW

A randomized, placebo-controlled phase 3 trial of the PI3Kδ inhibitor leniolisib for activated PI3Kδ syndrome

Interim Analysis of Safety and Hematological Parameters of an Ongoing Long-Term Open-Label Extension Study of Investigational PI3Kδ Inhibitor Leniolisib for Patients with Activated PI3K Delta Syndrome (APDS) through December 2021

Safety and Efficacy of Long Term Suppression of PI3Kinase Pathway By Small Molecule PI3K-Delta Inhibitor, Leniolisib in Apds (Activated PI3Kδ Syndrome)

Effective “activated PI3Kδ syndrome”–targeted therapy with the PI3Kδ inhibitor leniolisib

Minitransplant Using Repeated Unrelated Donor Lymphocyte Infusions as a Treatment of Immunodeficiency in Complete DiGeorge Syndrome.

Email alerts

ASH Publications

American Society of Hematology

A randomized, placebo-controlled phase 3 trial of the PI3Kδ inhibitor leniolisib for activated PI3Kδ syndrome

Interim Analysis of Safety and Hematological Parameters of an Ongoing Long-Term Open-Label Extension Study of Investigational PI3Kδ Inhibitor Leniolisib for Patients with Activated PI3K Delta Syndrome (APDS) through December 2021

Safety and Efficacy of Long Term Suppression of PI3Kinase Pathway By Small Molecule PI3K-Delta Inhibitor, Leniolisib in Apds (Activated PI3Kδ Syndrome)

Effective “activated PI3Kδ syndrome”–targeted therapy with the PI3Kδ inhibitor leniolisib

Minitransplant Using Repeated Unrelated Donor Lymphocyte Infusions as a Treatment of Immunodeficiency in Complete DiGeorge Syndrome.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only